Literature DB >> 14749187

Influenza H5 virus escape mutants: immune protection and antibody production in mice.

Yuri A Smirnov1, Asya K Gitelman, Elena A Govorkova, Aleksandr S Lipatov, Nikolai V Kaverin.   

Abstract

Avian H5N1 influenza A viruses are considered to be of high pandemic potential as they are able to cross the avian-human species barrier and cause disease in humans. In the present study we assessed the impact of amino acid substitutions in the hemagglutinin (HA) of antigenic escape mutants of influenza A/Mallard/Pennsylvania/10218/84 (H5N2) (Mld/PA/84-MA) virus on the level of neutralizing antibodies and the ability to protect mice against challenge with the wild type H5 influenza virus. beta-Propiolactone-inactivated vaccines prepared from eight different H5 escape mutants could be separated into two groups based on levels of protection. One group of escape mutants [m46(7), m46(7)-24B9, m46(7)-55, and m46(7)-55-24B9] was characterized by providing high levels of protection (90.0-95.4% survival) to mice against subsequent challenge with 5 LD(50) of wild type Mld/PA/84-MA virus. The other group of escape mutants [m176/26, m55(2), m55(2)-24B9, and m24B9-176/26] provided moderate level of protection (57.1-66.6% survival) in mice. Analysis of the amino acid substitutions in the HA revealed that two amino acid changes in antigenic site B of the HA molecule (D(126)-->N and K(152)-->N) were associated for decreases in the levels of antibody and the immune protection afforded by vaccination with these H5 virus escape mutants. The phenotypic effects of mutations in HA gene of H5 virus may be of importance to appraise the extent and direction of H5 influenza viruses antigenic evolution.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749187     DOI: 10.1016/j.virusres.2003.11.012

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  6 in total

1.  Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.

Authors:  Shigefumi Okamoto; Sumiko Matsuoka; Nobuyuki Takenaka; Ahmad M Haredy; Takeshi Tanimoto; Yasuyuki Gomi; Toyokazu Ishikawa; Takami Akagi; Mitsuru Akashi; Yoshinobu Okuno; Yasuko Mori; Koichi Yamanishi
Journal:  Clin Vaccine Immunol       Date:  2012-05-02

2.  Induction of heterosubtypic immunity to influenza virus by intranasal immunization.

Authors:  Fu-Shi Quan; Richard W Compans; Huan H Nguyen; Sang-Moo Kang
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

3.  Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs.

Authors:  Milton Thomas; Zhao Wang; Chithra C Sreenivasan; Ben M Hause; Feng Li; David H Francis; Radhey S Kaushik; Mahesh Khatri
Journal:  Vaccine       Date:  2014-11-28       Impact factor: 3.641

4.  Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides.

Authors:  Natalia Tarnovitski; Leslie J Matthews; Jianhua Sui; Jonathan M Gershoni; Wayne A Marasco
Journal:  J Mol Biol       Date:  2006-03-22       Impact factor: 5.469

Review 5.  Model answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planning.

Authors:  J McVernon; C T McCaw; J D Mathews
Journal:  Influenza Other Respir Viruses       Date:  2007-03       Impact factor: 4.380

Review 6.  Emerging viral infections.

Authors:  John R Su
Journal:  Clin Lab Med       Date:  2004-09       Impact factor: 1.935

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.